Elsevier MDL Upgrades MDL® Isentris® Platform
News Dec 08, 2005
Elsevier MDL has released an upgrade to the new-generation MDL® Isentris® informatics platform.
Elsevier claims that, the Isentris 1.4 release improves researchers' ability to collate and manage data within scientific workflows and to make decisions based on that data, providing the foundation for improved research productivity.
"Isentris 1.4 enhances the productivity and efficiency of scientists by making it easier for them to access complex data from multiple sources along with the appropriate visualization and analysis tools," said Vikki Rehn, Senior Vice President, Framework Business Group, Elsevier MDL.
"By enabling scientists to easily access and understand the data that is generated throughout the entire drug discovery and development process, Isentris 1.4 enables R&D teams to rapidly make informed, successful decisions."
Isentris supports a cohesive desktop research environment by rapidly integrating specialized in-house and third-party applications.
A growing community of companies, including Spotfire, InforSense and Tripos, in the MDL® Isentris® Alliance is utilizing the open technology framework to provide research organizations with integrated solutions.
Highlights of the MDL Isentris 1.4 release include - Simplified data access: Information can be centralized and automatically focused to address researchers' questions, avoiding information overload and project delays.
Re-usable workflows: Researchers can capture their questions and decision-making processes. These records can be saved, shared with colleagues, compared and re-run to improve productivity.
Improved workflows: Daily and weekly research workflows can be quickly configured to enable researchers' data to follow their data collation and decision-making needs.
Enriched data: Research information viewed in Isentris applications can be enriched from diverse sources, such as Web services or third-party calculators.
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE